Please check your internet connection and try again.
# Diadzein + Genistein + Palmitoylethanolamide
## Overview
This combination contains daidzein and genistein, which are isoflavones found in soy, and palmitoylethanolamide (PEA), a fatty acid amide. These compounds are often used as dietary supplements. Their therapeutic roles and established clinical uses are limited, and they are not typically considered first-line pharmacologic agents.
## Primary Indications
There are no FDA-approved indications for this combination. It is most commonly marketed for:
* Pain management (particularly neuropathic pain)
* Inflammation reduction
* Menopausal symptom relief
* General wellness
## Adult Dosing
Dosing varies significantly between products and is not standardized. Common regimens based on marketed products and research include:
* **Daidzein/Genistein:** Often combined, with total isoflavone doses ranging from 20 mg to 100 mg daily, divided into 1-2 doses.
* **Palmitoylethanolamide (PEA):** Doses typically range from 300 mg to 1200 mg daily, divided into 1-3 doses.
**Example Combination Regimen:** One product may suggest 200 mg PEA with 20 mg daidzein and 10 mg genistein, taken 1-2 times daily.
Actual dosing should be guided by the specific product's recommendations and the prescribing clinician's judgment.
## Pediatric Dosing
There is **no established pediatric dosing** for this combination. Use in pediatric populations is not supported by clinical evidence or regulatory approval.
## Dose Adjustments
No specific dose adjustments are established for renal or hepatic impairment due to the lack of formal pharmacokinetic studies. Caution is advised in patients with significant organ dysfunction.
## Contraindications
* Hypersensitivity to any component of the formulation.
* Pregnancy and breastfeeding (due to lack of safety data and potential hormonal effects of isoflavones).
## Adverse Effects
Adverse effects are generally uncommon and mild, but can include:
* Gastrointestinal upset (nausea, diarrhea)
* Headache
* Allergic reactions (rare)
## Key Drug Interactions
* **Hormone-sensitive conditions:** Isoflavones (daidzein, genistein) have weak estrogenic activity. Caution is advised in patients with a history of or predisposition to hormone-sensitive cancers (e.g., breast, uterine, ovarian).
* **Anticoagulants/Antiplatelets:** Soy isoflavones may have mild antiplatelet effects; concurrent use with anticoagulants or antiplatelet agents should be approached with caution, though significant clinical interactions are not well-documented.
* **Thyroid function:** High soy intake may interfere with thyroid hormone absorption or function in individuals with hypothyroidism or those taking thyroid medication.
## Monitoring
* Monitor for efficacy in the intended indication (e.g., pain levels, symptom severity).
* Monitor for adverse effects.
* Consider thyroid function tests if indicated based on patient history and soy intake.
## Clinical Pearls
* This combination is a dietary supplement and is not regulated by the FDA for safety and efficacy in the same way as prescription drugs.
* The quality and purity of supplements can vary.
* The specific synergistic or additive effects of this particular combination are not well-defined in clinical trials.
* Palmitoylethanolamide's mechanism of action is thought to involve modulating mast cell degranulation and interacting with the endocannabinoid system, but clinical evidence for efficacy in specific pain conditions is still evolving.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the full prescribing information and current guidelines before making clinical decisions. Product-specific information can vary widely for dietary supplements.
